ArticleJournal of clinical medicine2022
Global Burden and Improvement Gap of Non-Rheumatic Calcific Aortic Valve Disease: 1990-2019 Findings from Global Burden of Disease Study 2019.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- Global, regional, and national burden of non-rheumatic calcific aortic valve disease from 1990 to 2021, with projections of incidence to 2050: a systematic analysis of the global burden of disease study 2021 and Mendelian randomization analysis.Journal of cardiothoracic surgery · 2026Article
- Global burden of non-rheumatic calcific aortic valve disease in adults aged 60 years and older, with projections to 2041: insights from the Global Burden of Disease Study 2021.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Global, regional, and national burdens of non-rheumatic calcific aortic valve disease in middle-aged and elderly populations from 1990 to 2021 and predictions up to 2050: trends, predictions, and health inequity.European journal of medical research · 2025Article
- NETs accelerate aortic valve calcification by promoting M1 macrophage polarization through the TLR9 signaling pathway.Molecular and cellular biochemistry · 2025Article
- Partial upper sternotomyWorld journal of cardiology · 2025Article
- Global trends in staphylococcus aureus-related lower respiratory infections from 1990 to 2021: findings from the 2021 global burden of disease report.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Lipoprotein(a) and panvascular disease.Lipids in health and disease · 2025Review
- Global burden of ischemic heart disease attributable to ambient and household PMFrontiers in public health · 2025Article
- Global, regional, and national burden of non-rheumatic valvular heart disease and Its projections to 2035: comprehensive analysis of the global burden of disease study 2019.Frontiers in cardiovascular medicine · 2025Article
- Global, regional, and national burdens of heart failure in adolescents and young adults aged 10-24 years from 1990 to 2021: an analysis of data from the Global Burden of Disease Study 2021.EClinicalMedicine · 2025Article
- A comprehensive analysis of vitamin A deficiency in China from 1990 to 2021, examining temporal trends and demographic influences.Frontiers in nutrition · 2025Article
- Long-term trends in the burden of non-rheumatic calcific aortic valve disease in China from 1990 to 2021, with projections to 2050: results from the global burden of disease study.Frontiers in medicine · 2025Article
- Global burden of ischemic stroke attributable to physical inactivity among adults aged 55 and above: a 32-year analysis (1990-2021).Archives of medical science : AMS · 2025Article
- Non-rheumatic calcific aortic valve disease in China: findings from the Global Burden of Disease study 2021.Frontiers in cardiovascular medicine · 2025Article
- Global, regional, and national burden and quality of care of multiple myeloma, 1990-2019.Journal of global health · 2024Article
- Exploration and Validation of Immune and Therapeutic-Related Hub Genes in Aortic Valve Calcification and Carotid Atherosclerosis.Journal of inflammation research · 2024Article
- Alerting trends in epidemiology for calcific aortic valve disease, 1990-2019: An age-period-cohort analysis for the Global Burden of Disease Study 2019.European heart journal. Quality of care & clinical outcomes · 2023Article
- Focusing on the Native Matrix Proteins in Calcific Aortic Valve Stenosis.JACC. Basic to translational science · 2023Review
- Global, regional, and national time trends in disability-adjusted life years, mortality, and variable risk factors of non-rheumatic calcified aortic valve disease, 1990-2019: an age-period-cohort analysis of the Global Burden of Disease 2019 study.Journal of thoracic disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The aim of this study was to explore the most updated changing trends of non-rheumatic calcific aortic valve disease (nrCAVD) and reveal possible improvements. We analyzed the age-standardized rates (ASRs) of prevalence, incidence, disability-adjusted life-years (DALYs), and mortality trends of nrCAVD from 1990 to 2019 using data from the Global Burden of Disease (GBD) study 2019. The relations between ASRs and socio-demographic index (SDI) were analyzed with Pearson's correlation coefficients. Decomposition and frontier analysis were employed to reveal the contribution proportion of influence factors and regions where improvement can be achieved. In 2019, there were 9.40 million (95% uncertainty interval (UI): 8.07 to 10.89 million) individuals with nrCAVD globally. From 1990 to 2019, the prevalence rate of nrCAVD increased by 155.47% (95% IU: 141.66% to 171.7%), with the largest increase observed in the middle SDI region (821.11%, 95% UI: 709.87% to 944.23%). Globally, there were no significant changes in the mortality rate of nrCAVD (0.37%, 95% UI: -8.85% to 7.99%). The global DALYs decreased by 10.97% (95% UI: -17.94% to -3.46%). The population attributable fraction (PAF) of high systolic blood pressure increased in the population aged 15-49 years, while it declined slightly in population aged 50+ years. Population growth was the main contributing factor to the increased DALYs across the globe (74.73%), while aging was the driving force in the high-SDI region (80.27%). The Netherlands, Finland, Luxembourg, Germany, and Norway could reduce DALY rates of nrCAVD using their socio-demographic resources. According to these results, we revealed that the burden of nrCAVD increased markedly from 1990 to 2019 in high-SDI and high-middle-SDI regions. There was a downward trend in the mortality due to nrCAVD since 2013, which is possibly owing to profound advances in transcatheter aortic valve replacement. Some countries may reduce burdens of nrCAVD using their socio-demographic resources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.